Achieve Life Sciences Balance Sheet Health
Financial Health criteria checks 5/6
Achieve Life Sciences has a total shareholder equity of $10.7M and total debt of $14.9M, which brings its debt-to-equity ratio to 139.5%. Its total assets and total liabilities are $33.1M and $22.4M respectively.
Key information
139.55%
Debt to equity ratio
US$14.90m
Debt
| Interest coverage ratio | n/a |
| Cash | US$29.27m |
| Equity | US$10.68m |
| Total liabilities | US$22.43m |
| Total assets | US$33.11m |
Recent financial health updates
Recent updates
ACHV: Manufacturing Progress And Margin Potential Will Support Bullish Thesis
Analysts have reset their 12 month price target on Achieve Life Sciences to $21 from $25, citing updated views on future valuation multiples, margin potential and revenue ramp outlined in recent bullish research coverage. Analyst Commentary Recent Street research on Achieve Life Sciences points to a cluster of bullish views that frame the updated US$21, 12 month price target as part of a broader constructive stance on the stock.
Regulatory And Commercial Hurdles Will Test Smoking Cessation Catalyst Yet Long Term Potential Remains
Catalysts About Achieve Life Sciences Achieve Life Sciences is a biopharmaceutical company focused on bringing cytisinicline, a nicotine dependence treatment, to market for smoking and vaping cessation. What are the underlying business or industry changes driving this perspective?
Regulatory Tailwinds And Public Health Demand Will Support This Nicotine Cessation Opportunity
Catalysts About Achieve Life Sciences Achieve Life Sciences is a clinical stage biopharmaceutical company focused on developing cytisinicline as a treatment for nicotine dependence in smokers and vapers. What are the underlying business or industry changes driving this perspective?FDA Priority Voucher And Smoking Cessation Tailwinds Will Transform This Undervalued Biotech Story
Catalysts About Achieve Life Sciences Achieve Life Sciences is a biopharmaceutical company focused on developing and commercializing cytisinicline as a treatment for nicotine dependence in smokers and people who vape. What are the underlying business or industry changes driving this perspective?Achieve Life Sciences: Could Be The Best 'Tobacco' Stock For 2026 - Strong Buy
Summary Achieve Life Sciences is a late-stage Pharma company awaiting FDA approval for Cytisinicline, a novel (though proven) smoking cessation therapy, with a decision expected in June. Cytisinicline demonstrates superior efficacy and safety versus current treatments, with strong precedent in Europe and a large, underserved U.S. market. ACHV’s market cap (~$250M) is a fraction of its potential, with peak sales for smoking and vaping cessation possibly reaching $2–3 billion. I rate ACHV a strong buy, citing favorable approval odds and blockbuster potential, but note dilution and supply chain risks. Read the full article on Seeking AlphaIs Achieve Life Sciences (NASDAQ:ACHV) A Risky Investment?
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...Achieve Life Sciences: 1st Half 2025 NDA Filing On Track With FDA Agreement
Summary Achieve Life Sciences, Inc. initiated an open-label ORCA-OL trial using cytisinicline for smoking cessation; the Efficacy of the drug already established in several prior studies. Alignment with FDA that successful completion of ORCA-OL trial is necessary for NDA filing of cytisinicline in the 1st half of 2025. The global smoking cessation product market is estimated to reach $69.8 billion by the end of 2034. Potential label expansion opportunity exists of using cytisinicline for e-cigarettes or vaping cessation patients; End-of-phase 2 meeting expected in 2024. Read the full article on Seeking AlphaFinancial Position Analysis
Short Term Liabilities: ACHV's short term assets ($31.1M) exceed its short term liabilities ($11.8M).
Long Term Liabilities: ACHV's short term assets ($31.1M) exceed its long term liabilities ($10.6M).
Debt to Equity History and Analysis
Debt Level: ACHV has more cash than its total debt.
Reducing Debt: ACHV's debt to equity ratio has increased from 0% to 139.5% over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: ACHV has sufficient cash runway for 8 months based on last reported free cash flow, but has since raised additional capital.
Forecast Cash Runway: ACHV is forecast to have sufficient cash runway for 6 months based on free cash flow estimates, but has since raised additional capital.
Discover healthy companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/06/29 17:52 |
| End of Day Share Price | 2026/06/26 00:00 |
| Earnings | 2026/03/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Achieve Life Sciences, Inc. is covered by 13 analysts. 10 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Gary Nachman | Canaccord Genuity |
| null null | CG Capital |
| Gary Nachman | CGS International |